Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: Potential utility as biomarker?

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Lakota, Katja ^a   Wei, Jun ^b   Carns, Mary ^b   Hinchcliff, Monique ^b   Lee, Jungwha ^b   Whitfield, Michael L ^c   Sodin Semrl, Snezna ^a   Varga, John ^b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b NORTHWESTERN UNIVERSITY   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSFORMING GROWTH FACTOR BETA; BIOLOGICAL MARKER; TRANSCRIPTOME;

ADIPONECTIN BLOOD LEVEL; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME ACTIVITY; FEMALE; FIBROBLAST; GENE EXPRESSION; HUMAN; IN VITRO STUDY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MESENCHYME CELL; MODIFIED RODNAN SKIN SCORE; PROADIPOCYTE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN MICROARRAY; RATING SCALE; REAL TIME POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; BIOSYNTHESIS; BLOOD; DNA MICROARRAY; FIBROSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; FEMALE; FIBROSIS; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PPAR GAMMA; REAL-TIME POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; SKIN; TRANSCRIPTOME; YOUNG ADULT;

EID: 84860272867     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3827     Document Type: Article

References (28)

1. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28:1573-1576.
2. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009, 5:200-206. 10.1038/nrrheum.2009.26, 19337284.
3. Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, Whitfield ML. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010, 130:694-705. 10.1038/jid.2009.318, 19812599.
4. Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2004, 50:1305-1318. 10.1002/art.20104, 15077315.
5. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77:289-312. 10.1146/annurev.biochem.77.061307.091829, 18518822.
6. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21:365-371. 10.1161/01.ATV.21.3.365, 11231915.
7. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47:507-514. 10.2337/diabetes.47.4.507, 9568680.
8. Wei J, Bhattacharyya S, Varga J. Peroxisome proliferator-activated receptor gamma: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol 2010, 22:671-676. 10.1097/BOR.0b013e32833de1a7, 20693905.
9. Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnet M, Phipps RP, Sime PJ. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005, 288:L1146-1153. 10.1152/ajplung.00383.2004, 15734787.
10. Kulkarni AA, Thatcher TH, Olsen KC, Maggirwar SB, Phipps RP, Sime PJ. PPAR-gamma ligands repress TGFbeta-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis. PLoS One 2011, 6:e15909. 10.1371/journal.pone.0015909, 3017065, 21253589.
11. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 2009, 174:519-533. 10.2353/ajpath.2009.080574, 2630560, 19147827.
12. Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ, Leask A. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 2009, 60:2822-2829. 10.1002/art.24761, 19714649.
13. Shi-wen X, Eastwood M, Stratton RJ, Denton CP, Leask A, Abraham DJ. Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology (Oxford) 2010, 49:259-263.
14. Wei J, Ghosh AK, Sargent JL, Komura K, Wu M, Huang QQ, Jain M, Whitfield ML, Feghali-Bostwick C, Varga J. PPARgamma downregulation by TGFss in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010, 5:e13778. 10.1371/journal.pone.0013778, 2970611, 21072170.
15. Kusminski CM, Scherer PE. The road from discovery to clinic: adiponectin as a biomarker of metabolic status. Clin Pharmacol Ther 2009, 86:592-595. 10.1038/clpt.2009.155, 19915603.
16. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, Whitfield ML. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008, 3:e2696. 10.1371/journal.pone.0002696, 2481301, 18648520.
17. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002, 51:2734-2741. 10.2337/diabetes.51.9.2734, 12196466.
18. Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 2009, 48:1595-1599.
19. Phillips SA, Kung JT. Mechanisms of adiponectin regulation and use as a pharmacological target. Curr Opin Pharmacol 2010, 10:676-683. 10.1016/j.coph.2010.08.002, 20810317.
20. Arakawa H, Jinnin M, Muchemwa FC, Makino T, Kajihara I, Makino K, Honda N, Sakai K, Fukushima S, Ihn H. Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients. Exp Dermatol 2011, 20:764-766. 10.1111/j.1600-0625.2011.01310.x, 21615510.
21. De Sanctis JB, Zabaleta M, Bianco NE, Garmendia JV, Rivas L. Serum adipokine levels in patients with systemic lupus erythematosus. Autoimmunity 2009, 42:272-274. 10.1080/08916930902828031, 19811274.
22. Rho YH, Solus J, Sokka T, Oeser A, Chung CP, Gebretsadik T, Shintani A, Pincus T, Stein CM. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 2009, 60:1906-1914. 10.1002/art.24626, 2894567, 19565493.
23. Sada KE, Yamasaki Y, Maruyama M, Sugiyama H, Yamamura M, Maeshima Y, Makino H. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 2006, 33:1545-1552.
24. Toussirot E, Gaugler B, Bouhaddi M, Nguyen NU, Saas P, Dumoulin G. Elevated adiponectin serum levels in women with systemic autoimmune diseases. Mediators Inflamm 2010, 2010:938408. 3017955, 21234350.
25. Chizzolini C, Brembilla NC, Montanari E, Truchetet ME. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 2011, 10:276-281. 10.1016/j.autrev.2010.09.016, 20863906.
26. Ezure T, Amano S. Adiponectin and leptin up-regulate extracellular matrix production by dermal fibroblasts. Biofactors 2007, 31:229-236. 10.1002/biof.5520310310, 18997286.
27. Handy JA, Saxena NK, Fu P, Lin S, Mells JE, Gupta NA, Anania FA. Adiponectin activation of AMPK disrupts leptin-mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS-3). J Cell Biochem 2010, 110:1195-1207. 10.1002/jcb.22634, 2907429, 20564215.
28. Masui Y, Asano Y, Shibata S, Noda S, Aozasa N, Akamata K, Yamada D, Tamaki Z, Tada Y, Sugaya M, Sato S, Kadono T. Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. J Eur Acad Dermatol Venereol 2012, 26:354-360. 10.1111/j.1468-3083.2011.04077.x, 21504484.